Abstract:Atherosclerosis research typically focuses on the evolution of intermediate or advanced atherosclerotic lesions rather than on prelesional stages of atherogenesis. Yet these early events may provide decisive leads on the triggers of the pathologic process, before lesions become clinically overt. Thereby, it is mandatory to consider extracellular lipoprotein deposition at this stage as the prerequisite of foam cell formation leading to a remarkable accumulation of LDL (Low Density Lipoproteins). As progression of atherosclerosis displays the characteristic features of a chronic inflammatory process on the one hand and native LDL lacks inflammatory properties on the other hand, the lipoprotein must undergo biochemical modification to become atherogenic. During the last 25 years, evidence was accumulated in support of a different concept on atherogenesis proposing that modification of native LDL occurs through the action of ubiquitous hydrolytic enzymes (enzymatically modified LDL or eLDL) rather than oxidation and contending that the physiological events leading to macrophage uptake and reverse transport of eLDL first occur without inflammation (initiation with reversion). Preventing or reversing initial atherosclerotic lesions would avoid the later stages and therefore prevent clinical manifestations. This concept is in accordance with the response to retention hypothesis directly supporting the strategy of lowering plasma levels of atherogenic lipoproteins as the most successful therapy for atherosclerosis and its sequelae. Apart from but unquestionable closely related to this concept, there are several other hypotheses on atherosclerotic lesion initiation favoring an initiating role of the immune system ('vascular-associated lymphoid tissue' (VALT)), defining foam cell formation as a variant of lysosomal storage disease, relating to the concept of the inflammasome with crystalline cholesterol and/or mitochondrial DAMPs (damage-associated molecular patterns) being mandatory in driving arterial inflammation and, last but not least, pointing to miRNAs (micro RNAs) as pivotal players. However, direct anti-inflammatory therapies may prove successful as adjuvant components but will likely never be used in the absence of strategies to lower plasma levels of atherogenic lipoproteins, the key point of the perception that atherosclerosis is not simply an inevitable result of senescence. In particular, given the importance of chemical modifications for lipoprotein atherogenicity, regulation of the enzymes involved might be a tempting target for pharmacological research.

HDL and plaque regression in a multiphase model of early atherosclerosis

HDL and plaque regression in a multiphase model of early atherosclerosis

A new lipid-structured model to investigate the opposing effects of LDL and HDL on atherosclerotic plaque macrophages

Estimating Current and Long-Term Risks of Coronary Artery in Silico by Fractional Flow Reserve, Wall Shear Stress and Low-Density Lipoprotein Filtration Rate

Macrophage Anti-inflammatory Behaviour in a Multiphase Model of Atherosclerotic Plaque Development

A Two-Phase Model of Early Atherosclerotic Plaque Development with LDL Toxicity Effects

A Lipid-Structured Model of Atherosclerotic Plaque Macrophages with Lipid-Dependent Kinetics

Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis

A two-phase model of early fibrous cap formation in atherosclerosis

Mechanistic insights into the regression of atherosclerotic plaques

Blood lipoproteins shape the phenotype and lipid content of early atherosclerotic lesion macrophages: a dual-structured mathematical model

HDL Promotes Rapid Atherosclerosis Regression in Mice and Alters Inflammatory Properties of Plaque Monocyte-Derived Cells.

A Lipid-Structured Model of Atherosclerosis with Macrophage Proliferation

Dynamical Model of Mild Atherosclerosis: Applied Mathematical Aspects

Stage-specific Remodeling of Atherosclerotic Lesions Upon Cholesterol Lowering in LDL Receptor Knockout Mice.

The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection

A multiphase model of growth factor-regulated atherosclerotic cap formation

The cellular biology of atherosclerosis with atherosclerotic lesion classification and biomarkers

A mathematical model for smooth muscle cell phenotype switching in atherosclerotic plaque

George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry.

Analysis and numerical simulation of a reaction–diffusion mathematical model of atherosclerosis